+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 5 Actively Recruiting clinical trials

R

Actively Recruiting

Researchers are evaluating whether the drugs retatrutide and tirzepatide can prevent major adverse liver outcomes MALO in adults with metabolic dysfunction-associated steatotic liver disease MASLD, a condition that puts them at higher risk for severe liver problems. This Phase 3 trial is designed as a randomized, controlled study involving about 4,500 adults with MASLD identified through non-invasive tests indicating increased risk for liver complications. Participants will be randomly assigned to receive either retatrutide, tirzepatide, or a placebo, all given by subcutaneous injection. The study will last approximately 224 weeks, with up to 25 to 30 clinic visits to monitor health, conduct procedures, and assess liver function and disease progression. After completing the main study, eligible participants may join an optional 2-year extension where all receive either retatrutide or tirzepatide, regardless of initial assignment. Throughout the trial, participants will undergo assessments including liver fat content measurements, liver stiffness tests, liver fibrosis scores, and blood tests for liver enzymes and body weight changes. The primary outcome is the time until the first major adverse liver event occurs. Safety and disease progression will be closely monitored during and after treatment through regular clinic visits and evaluations.

Age: 18Years +All GendersPhase 3
563 locations
M

Actively Recruiting

Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.

Age: 18Years +All Genders
2393 locations
S

Actively Recruiting

Researchers are evaluating whether combining mirikizumab with tirzepatide can reduce or eliminate symptoms of moderately to severely active ulcerative colitis UC and help participants lose at least 10% of their body weight. This phase 3b study focuses on adults with UC who are also obese or overweight, comparing treatment with mirikizumab plus tirzepatide against mirikizumab plus placebo. The study is sponsored by Eli Lilly and Company and aims to better understand treatment effects on UC symptoms and weight loss. Participants receive mirikizumab first by intravenous infusion, followed by subcutaneous injections of mirikizumab. They are randomly assigned to also receive either tirzepatide or a placebo via subcutaneous injection. Treatment lasts up to 52 weeks. The study is double-blinded, so neither participants nor researchers know who receives tirzepatide or placebo during the trial. Throughout the study, participants undergo regular monitoring including clinical assessments to evaluate remission and response of UC symptoms, endoscopic exams, and histologic evaluations. Researchers measure the percentage of participants who achieve both clinical remission and significant weight loss at week 52. The total participation time is up to 61 weeks, including screening and treatment. Safety and effectiveness are closely tracked during and after treatment.

Age: 18Years - 70YearsAll GendersPhase 3
186 locations
S

Actively Recruiting

This trial investigates the safety and effectiveness of mirikizumab combined with tirzepatide versus mirikizumab with placebo in adults who have moderately to severely active Crohns disease along with obesity or overweight. The study is a phase 3b clinical trial and aims to assess how well these treatments work together to improve disease activity and reduce weight. Participants are randomly assigned to one of two groups one receives mirikizumab intravenously followed by subcutaneous administration along with tirzepatide given subcutaneously the other group receives mirikizumab in the same way but with a placebo injection instead of tirzepatide. Treatments are given according to a defined schedule over the course of the study, which lasts up to 61 weeks. Throughout the trial, participants undergo regular monitoring including clinical assessments for Crohns disease activity, endoscopic evaluations, and measurements of body weight. Researchers track outcomes like clinical remission, endoscopic remission, and weight loss at various time points, especially at Week 52. Safety and tolerability are also carefully observed during the study period that may extend up to 61 weeks.

Age: 18Years - 70YearsAll GendersPhase 3
183 locations
P

Actively Recruiting

Crohns disease is a long-lasting condition causing severe inflammation in the digestive tract, mainly affecting the bowels. Symptoms include belly pain, diarrhea, tiredness, and weight loss. This study evaluates targeted therapies for adults with moderate to severe Crohns disease, aiming to understand their effectiveness and side effects. The trial is a Phase 2a randomized platform study involving about 590 participants worldwide. Participants will be randomly assigned to receive one of several treatments risankizumab, trosunilimab, lutikizumab, or ABBV-8736, administered either by injection under the skin or infusion into the vein. Some groups receive combination therapies involving different doses and delivery methods. A long-term extension allows risankizumab monotherapy for up to 72 weeks. Treatments are given at hospitals or clinics in scheduled visits. During the study, participants attend regular visits for medical assessments including blood tests, endoscopies, and questionnaires. Researchers monitor treatment effects, side effects, and disease activity using tools like endoscopic remission and clinical remission scores. Safety and adverse events are tracked up to approximately 96 weeks. Participants keep daily diaries and complete questionnaires to aid data collection.

Age: 18Years - 75YearsAll GendersPhase 2
255 locations